Stoke Therapeutics Inc. (NASDAQ: STOK) stock fell -1.78% on Friday to $4.98 against a previous-day closing price of $5.07. With 0.79 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.43 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.2050 whereas the lowest price it dropped to was $4.9200. The 52-week range on STOK shows that it touched its highest point at $17.10 and its lowest point at $4.90 during that stretch. It currently has a 1-year price target of $21.00. Beta for the stock currently stands at 0.35.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of STOK was down-trending over the past week, with a drop of -6.21%, but this was down by -8.62% over a month. Three-month performance dropped to -61.48% while six-month performance fell -45.21%. The stock lost -70.25% in the past year, while it has lost -46.05% so far this year. A look at the trailing 12-month EPS for STOK yields -2.54 with Next year EPS estimates of -2.57. For the next quarter, that number is -0.63. This implies an EPS growth rate of -11.30% for this year and -2.80% for next year.
Float and Shares Shorts:
At present, 44.19 million STOK shares are outstanding with a float of 41.88 million shares on hand for trading. On Aug 30, 2023, short shares totaled 4.63 million, which was 10.47% higher than short shares on Jul 30, 2023. In addition to Dr. Edward M. Kaye M.D., Ph.D. as the firm’s CEO & Director, Dr. Adrian R. Krainer Ph.D. serves as its Co-Founder & Independent Director.
Through their ownership of 103.84% of STOK’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 84.97% of STOK, in contrast to 56.87% held by mutual funds. Shares owned by individuals account for 15.94%. As the largest shareholder in STOK with 9.92% of the stake, RTW Investments LP holds 4,390,558 shares worth 4,390,558. A second-largest stockholder of STOK, Redmile Group LLC, holds 3,955,188 shares, controlling over 8.94% of the firm’s shares. Cowen & Co. LLC is the third largest shareholder in STOK, holding 3,721,659 shares or 8.41% stake. With a 2.33% stake in STOK, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 1,029,440 shares are owned by the mutual fund manager. The Xtrackers SICAV – CSI300 Swap UCI, which owns about 1.59% of STOK stock, is the second-largest Mutual Fund holder. It holds 701,939 shares valued at 3.94 million. iShares Russell 2000 ETF holds 1.40% of the stake in STOK, owning 619,220 shares worth 3.48 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, STOK reported revenue of $3.23M and operating income of -$25.24M. The EBITDA in the recently reported quarter was -$25.24M and diluted EPS was -$0.63.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for STOK since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With STOK analysts setting a high price target of $35.00 and a low target of $12.00, the average target price over the next 12 months is $21.00. Based on these targets, STOK could surge 602.81% to reach the target high and rise by 140.96% to reach the target low. Reaching the average price target will result in a growth of 321.69% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded STOK stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 16,948 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 0 while 106,948 shares were sold.